FTM
SYRE icon

First Turn Management’s Spyre Therapeutics SYRE Stock Holding History

First Turn Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-464,435
Closed -$10.9M – 49
2024
Q2 		$10.9M Hold
464,435
– – 1.78% 30
2024
Q1 		$17.6M Buy
+464,435
New +$13.5M 2.64% 20

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Turn Management's SYRE Position: Q3 2024 in Review

First Turn Management sold out of Spyre Therapeutics (SYRE) in Q3 2024, closing a stake of 464,435 shares — an estimated $10.9M sold.

First Turn Management first reported a position in SYRE in Q1 2024 and held it in 2 quarters. The position peaked at $17.6M in Q1 2024. 119 funds tracked by Wall St. Rank hold SYRE as of Q3 2024.

  • First Turn Management reported no remaining Spyre Therapeutics position as of Q3 2024 after selling out during the quarter.
  • First Turn Management sold 464,435 Spyre Therapeutics shares in Q3 2024, an estimated $10.9M.
  • First Turn Management first reported a position in Spyre Therapeutics in Q1 2024 and held it in 2 quarters.
  • First Turn Management's Spyre Therapeutics position peaked at $17.6M in Q1 2024.
  • 119 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2024.

Based on First Turn Management's 13F filing for Q3 2024, filed 7 Nov 2024.